PL368572A1 - Preparat farmaceutyczny do stosowania w profilaktyce i leczeniu podwyższonego poziomu cholesterolu,LDL oraz trójglicerydów oraz zastosowanie preparatu farmaceutycznego jako czynnika przeciwmiażdżycowego stosowanego w schorzeniach układu krążenia - Google Patents

Preparat farmaceutyczny do stosowania w profilaktyce i leczeniu podwyższonego poziomu cholesterolu,LDL oraz trójglicerydów oraz zastosowanie preparatu farmaceutycznego jako czynnika przeciwmiażdżycowego stosowanego w schorzeniach układu krążenia

Info

Publication number
PL368572A1
PL368572A1 PL04368572A PL36857204A PL368572A1 PL 368572 A1 PL368572 A1 PL 368572A1 PL 04368572 A PL04368572 A PL 04368572A PL 36857204 A PL36857204 A PL 36857204A PL 368572 A1 PL368572 A1 PL 368572A1
Authority
PL
Poland
Prior art keywords
pharmaceutical compound
affections
ldl
triglycerides
cholesterol
Prior art date
Application number
PL04368572A
Other languages
English (en)
Inventor
Radosław Piotr Radzki
Marek Bieńko
Stefan Pierzynowski
Original Assignee
Sgp & Sons Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgp & Sons Ab filed Critical Sgp & Sons Ab
Priority to PL04368572A priority Critical patent/PL368572A1/pl
Priority to KR1020077001068A priority patent/KR101212583B1/ko
Priority to EP05752599A priority patent/EP1755580A1/en
Priority to JP2007516436A priority patent/JP4927721B2/ja
Priority to CA002568902A priority patent/CA2568902A1/en
Priority to AU2005253914A priority patent/AU2005253914B2/en
Priority to CN2005800200929A priority patent/CN101001620B/zh
Priority to RU2006143803/15A priority patent/RU2375055C2/ru
Priority to US11/629,398 priority patent/US20080027139A1/en
Priority to HK08100710.1A priority patent/HK1107018B/xx
Priority to PCT/SE2005/000929 priority patent/WO2005123056A1/en
Publication of PL368572A1 publication Critical patent/PL368572A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
PL04368572A 2004-06-17 2004-06-17 Preparat farmaceutyczny do stosowania w profilaktyce i leczeniu podwyższonego poziomu cholesterolu,LDL oraz trójglicerydów oraz zastosowanie preparatu farmaceutycznego jako czynnika przeciwmiażdżycowego stosowanego w schorzeniach układu krążenia PL368572A1 (pl)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PL04368572A PL368572A1 (pl) 2004-06-17 2004-06-17 Preparat farmaceutyczny do stosowania w profilaktyce i leczeniu podwyższonego poziomu cholesterolu,LDL oraz trójglicerydów oraz zastosowanie preparatu farmaceutycznego jako czynnika przeciwmiażdżycowego stosowanego w schorzeniach układu krążenia
KR1020077001068A KR101212583B1 (ko) 2004-06-17 2005-06-16 혈장 지질을 낮추기 위한 알파 케토글루타레이트 및 관련화합물의 용도
EP05752599A EP1755580A1 (en) 2004-06-17 2005-06-16 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids
JP2007516436A JP4927721B2 (ja) 2004-06-17 2005-06-16 α−ケトグルタル酸及び関連化合物の血漿中脂質を低下させるための使用
CA002568902A CA2568902A1 (en) 2004-06-17 2005-06-16 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids
AU2005253914A AU2005253914B2 (en) 2004-06-17 2005-06-16 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids
CN2005800200929A CN101001620B (zh) 2004-06-17 2005-06-16 α-酮基戊二酸和相关化合物用于降低血脂的用途
RU2006143803/15A RU2375055C2 (ru) 2004-06-17 2005-06-16 Применение альфа-кетоглутарата и родственных соединений для снижения липидов плазмы
US11/629,398 US20080027139A1 (en) 2004-06-17 2005-06-16 Use of Alpha-Ketoglutarate and Related Compounds
HK08100710.1A HK1107018B (en) 2004-06-17 2005-06-16 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids
PCT/SE2005/000929 WO2005123056A1 (en) 2004-06-17 2005-06-16 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL04368572A PL368572A1 (pl) 2004-06-17 2004-06-17 Preparat farmaceutyczny do stosowania w profilaktyce i leczeniu podwyższonego poziomu cholesterolu,LDL oraz trójglicerydów oraz zastosowanie preparatu farmaceutycznego jako czynnika przeciwmiażdżycowego stosowanego w schorzeniach układu krążenia

Publications (1)

Publication Number Publication Date
PL368572A1 true PL368572A1 (pl) 2005-12-27

Family

ID=35509438

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04368572A PL368572A1 (pl) 2004-06-17 2004-06-17 Preparat farmaceutyczny do stosowania w profilaktyce i leczeniu podwyższonego poziomu cholesterolu,LDL oraz trójglicerydów oraz zastosowanie preparatu farmaceutycznego jako czynnika przeciwmiażdżycowego stosowanego w schorzeniach układu krążenia

Country Status (10)

Country Link
US (1) US20080027139A1 (pl)
EP (1) EP1755580A1 (pl)
JP (1) JP4927721B2 (pl)
KR (1) KR101212583B1 (pl)
CN (1) CN101001620B (pl)
AU (1) AU2005253914B2 (pl)
CA (1) CA2568902A1 (pl)
PL (1) PL368572A1 (pl)
RU (1) RU2375055C2 (pl)
WO (1) WO2005123056A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL226695B1 (pl) * 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
MX2009013937A (es) * 2007-07-02 2010-04-30 Entress Ab Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.
KR101610791B1 (ko) 2007-07-03 2016-04-11 다누타 크루셰프스카 알파­케토글루타레이트의 의약 용도
JP4996527B2 (ja) * 2008-04-14 2012-08-08 日本特殊陶業株式会社 積層型ガスセンサ素子及びガスセンサ
CN105029086A (zh) * 2015-08-26 2015-11-11 中国科学院亚热带农业生态研究所 a-酮戊二酸二钠在制备猪饲料中的应用
CN105029087A (zh) * 2015-08-26 2015-11-11 中国科学院亚热带农业生态研究所 a-酮戊二酸二钾在制备猪饲料中的应用
CN105076722A (zh) * 2015-08-26 2015-11-25 中国科学院亚热带农业生态研究所 a-酮戊二酸二钠在制备家禽饲料中的应用
CN107412216B (zh) * 2017-07-26 2020-08-07 华南农业大学 α-酮戊二酸在改善高脂饮食导致的动物繁殖功能损伤方面的应用
KR102833111B1 (ko) * 2018-09-25 2025-07-10 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 칼슘 알파-케토글루타레이트의 제조 방법
CN121038861A (zh) 2023-04-13 2025-11-28 3M创新有限公司 呼吸防护装置及其制造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542929A (en) * 1966-02-23 1970-11-24 Hope City Chemotherapeutic compositions useful in animal detoxification
SE9303691D0 (sv) * 1993-11-09 1993-11-09 Gramineer Ab New beverage
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
EP1032403B1 (en) * 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US6277431B1 (en) * 1998-10-14 2001-08-21 Redeem, Inc. Anticholesterolemic edible oil

Also Published As

Publication number Publication date
AU2005253914B2 (en) 2011-06-30
CA2568902A1 (en) 2005-12-29
US20080027139A1 (en) 2008-01-31
RU2375055C2 (ru) 2009-12-10
KR101212583B1 (ko) 2012-12-14
EP1755580A1 (en) 2007-02-28
HK1107018A1 (zh) 2008-03-28
AU2005253914A1 (en) 2005-12-29
WO2005123056A1 (en) 2005-12-29
RU2006143803A (ru) 2008-07-27
JP2008502679A (ja) 2008-01-31
CN101001620A (zh) 2007-07-18
CN101001620B (zh) 2010-06-16
JP4927721B2 (ja) 2012-05-09
KR20070040371A (ko) 2007-04-16

Similar Documents

Publication Publication Date Title
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
PL2292219T4 (pl) Transdermalny system terapeutyczny
EP2097012A4 (en) DEVICES AND METHOD FOR TREATING HEART FAILURE
WO2008127349A3 (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
IL198743A0 (en) Transdermal therapeutic system for administering the active substance buprenorphine
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
PL2040713T3 (pl) Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
PT1655037E (pt) Agente redutor de colesterol sérico ou agente preventivo ou terapêutico para o tratamento de aterosclerose
IL197212A0 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2007025005A3 (en) Sustained release formulations of nalbuphine
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
PL368572A1 (pl) Preparat farmaceutyczny do stosowania w profilaktyce i leczeniu podwyższonego poziomu cholesterolu,LDL oraz trójglicerydów oraz zastosowanie preparatu farmaceutycznego jako czynnika przeciwmiażdżycowego stosowanego w schorzeniach układu krążenia
PT1596868E (pt) Método para o tratamento de insuficiência cardíaca grave e medicamento associado
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2005096704A3 (en) Cholesterol lowering composition
EP1950209A4 (en) TREATMENT AGENT FOR CIRCULATORY INSUFFICIENCY
EP1968561B8 (en) Treatment of diabetic nephropathy
WO2008051793A3 (en) Method of preventing or treating metabolic syndrome
MX2007013301A (es) Agente profilactico/terapeutico para la anormalidades del metabolismo del azucar/lipidos.
WO2009047505A3 (en) Dexanabinol with inhibitors of braf or mek for the treatment of melanoma

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)